Brief: Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models

Palisade Bio

21/05/2024 13:32

May 21 (Reuters) - Palisade Bio Inc  PALI.O :
    * PALISADE BIO’S LEAD PRODUCT CANDIDATE, PALI-2108
DEMONSTRATES
LOCAL BIOACTIVATION AND DOSE DEPENDENT EFFICACY RESPONSE IN
PRECLINICAL MOUSE MODELS
    * PALISADE BIO INC - PRECLINICAL DATA DEMONSTRATE PALI-2108
TO BE
SAFE, EFFECTIVE, AND WELL TOLERATED
    * PALISADE BIO INC - COMPANY ON TRACK TO COMMENCE PHASE 1
HUMAN
CLINICAL STUDY OF LEAD PRODUCT CANDIDATE, PALI-2108, FOR
TREATMENT OF UC BEFORE YEAR END

Source text for Eikon:  ID:nGNX1TrcM8 
Further company coverage:  PALI.O 

 ((Reuters.Briefs@thomsonreuters.com;))